A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonists
Top Cited Papers
Open Access
- 27 February 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (3) , 1010-1020
- https://doi.org/10.1002/art.22382
Abstract
Objective Microarray analyses of peripheral blood leukocytes have shown that patients with systemic lupus erythematosus express increased levels of type I interferon (IFN)–regulated genes. In this study we examined gene expression by peripheral blood mononuclear cells (PBMCs) from patients with systemic sclerosis (SSc) to better understand the dysregulation of the immune system in this disease. Methods PBMC gene expression was analyzed by microarray and confirmed by real-time polymerase chain reaction (PCR). Surface protein expression of Siglec-1 was analyzed by flow cytometry in PBMCs from healthy control subjects and patients with SSc, and in control PBMCs that were cultured in vitro with Toll-like receptor (TLR) agonists. Results SSc patients showed increased expression of a cluster of IFN-regulated genes, including Siglec-1 (CD169, sialoadhesin). This result was verified and extended by real-time PCR, showing that a subset of the SSc patients expressed strikingly increased levels of Siglec-1 messenger RNA (mRNA). Flow cytometry of PBMCs from SSc patients and healthy controls showed increased Siglec-1 surface protein expression, which was restricted to CD14+ monocytes. In vitro studies showed that type I IFN and certain TLR agonists, including TLR-7 and TLR-9, induced Siglec-1 mRNA and protein expression. Moreover, TLR induction of surface Siglec-1 was shown to be type I IFN–dependent. Increased numbers of Siglec-1+ cells were observed by immunohistochemistry in the skin of SSc patients compared with healthy controls. Conclusion Increased expression of Siglec-1 in circulating SSc monocytes and tissue macrophages suggests that type I IFN–mediated activation of monocytes occurs in SSc, possibly through TLR activation of IFN secretion. These observations indicate a potential role for type I IFN–activated monocyte/macrophages in the pathogenesis of SSc.Keywords
This publication has 44 references indexed in Scilit:
- Pivotal Advance: Activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163Journal of Leukocyte Biology, 2006
- Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patientsRheumatology, 2006
- IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell PrecursorsAnnual Review of Immunology, 2005
- Fibulin-2 and Fibulin-5 Alterations in Tsk Mice Associated with Disorganized Hypodermal Elastic Fibers and Skin TetheringJournal of Investigative Dermatology, 2004
- Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubationGenes & Immunity, 2004
- Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril‐associated glycoprotein 2 and type I collagenArthritis & Rheumatism, 2004
- Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus BloodThe Journal of Experimental Medicine, 2003
- Analysis of an Interaction between the Soluble Vaccinia Virus-Coded Type I Interferon (IFN)-Receptor and Human IFN-α1 and IFN-α2Virology, 1997
- Sialoadhesin on macrophages: its identification as a lymphocyte adhesion molecule.The Journal of Experimental Medicine, 1992
- Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With SclerodermaArthritis & Rheumatism, 1992